Results of a phase 3, randomized study of patients with advanced renal cell carcinoma (RCC) and poor prognostic features treated with temsirolimus, interferon-alpha or the combination of temsirolimus plus interferon-alpha
EJC Supplements. 2007 Sep;5(4):282-3.
Abstract